However, patients with EGFR overexpressing tumours (⩾85% tumour cell staining) demonstrated a significantly worse prognosis (35.0 months (23.0–58.0)) than those with no overexpression (87.0 months (69.0–103.0)). This evidence concerns the gene EGFR and neoplasm.